Lumasiran: a potential therapy for the management of primary hyperoxaluria type 1? An editorial
- PMID: 36799810
- PMCID: PMC10389315
- DOI: 10.1097/JS9.0000000000000143
Lumasiran: a potential therapy for the management of primary hyperoxaluria type 1? An editorial
Conflict of interest statement
All authors have equally contributed to the manuscript and have approved the final manuscript to be published.
Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Comment on
-
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.Clin J Am Soc Nephrol. 2021 Jul;16(7):1025-1036. doi: 10.2215/CJN.14730920. Epub 2021 May 13. Clin J Am Soc Nephrol. 2021. PMID: 33985991 Free PMC article. Clinical Trial.
References
-
- Watts RWE. Primary hyperoxaluria. Contrib Nephrol 1997;122:143–159. - PubMed
-
- Cochat P, Deloraine A, Rotily M, et al. . Epidemiology of primary hyperoxaluria type 1. Nephrol Dial Transplant 1995;10(suppl 8):3–7. - PubMed
-
- Talati JJ, Hulton SA, Garrelfs SF, et al. . Primary hyperoxaluria in populations of Pakistan origin: results from a literature review and two major registries. Urolithiasis 2018;46:187–195. - PubMed
-
- Gibbs DA, Watts RW. The action of pyridoxine in primary hyperoxaluria. Clin Sci 1969;37:565. - PubMed
-
- Cochat P, Hulton SA, Acquaviva C, et al. . Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 2012;27:1729–1736. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources